Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Re:NewCell on its IPO
Mandate

Vinge advises Re:NewCell on its IPO

November 27, 2020 Banking and Finance M&A Corporate Tax Capital Markets and Public M&A

Vinge advises Re:NewCell AB in connection with its listing on Nasdaq First North Premier Growth Market.

The company is the first in the world to commercially offer a dissolving pulp for textile production manufactured from 100 per cent recycled textiles.

The Vinge team includes Christian Lindhé, Erik Sjöman, Ludvig Frithiof and Nora Gullberg (Capital Markets and Public M&A), Henrik Ossborn and Jack Bengtsson (Banking and Finance), Anna Edström and Martin Svanberg (M&A) as well as Maria Schultzberg (Tax).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025